Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Thomas P Corner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield …. Hauptthemen laut MEDLINE: gamma-Butyrobetaine Dioxygenase, Hypoxia-Inducible Factor-Proline Dioxygenases, Prolyl-Hydroxylase Inhibitors, Enzyme Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Royal Commission for the Exhibition of 1851, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
The 2-oxoglutarate (2OG)/Fe(II)-dependent γ-butyrobetaine hydroxylase (BBOX) catalyzes the final step in l-carnitine biosynthesis, i.e., stereoselective C-3 oxidation of γ-butyrobetaine (GBB). BBOX inhibition is a validated clinical strategy to modulate l-carnitine levels and to enhance cardiovascular efficiency. Reported BBOX inhibitors, including the clinically used cardioprotective agent Mildronate, manifest moderate inhibitory activity in vitro, limited selectivity, and/or unfavorable physicochemical properties, indicating a need for improved BBOX inhibitors. We report that the clinically used hypoxia-inducible factor-α prolyl residue hydroxylase (PHD) inhibitors Desidustat, Enarodustat, and Vadadustat efficiently inhibit isolated recombinant BBOX, suggesting that BBOX inhibition by clinically used PHD inhibitors should be considered as a possible off-target effect. Structure-activity relationship studies on the Desidustat scaffold enabled development of potent BBOX inhibitors that manifest high levels of selectivity for BBOX inhibition over representative human 2OG oxygenases, including PHD2. The Desidustat derivatives will help to enable investigations into the biological roles of l-carnitine and the therapeutic potential of BBOX inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, U.K.
- Institute of Natural Medicine, University of Toyama, 2630-Sugitani, Toyama 930-0194, Japan.
- Department of Biochemistry, Faculty of Science, King AbdulAziz University, Jeddah 21589, Saudi Arabia.
ORCID-Profile: Thomas P Corner, Yu Nakashima, Lara I Schnaubelt, Lennart Brewitz, Christopher J Schofield
Förderung
- Wellcome Trust
- Royal Commission for the Exhibition of 1851
- Biotechnology and Biological Sciences Research Council
- Cancer Research UK
Zitieren
APA
Corner, T. P., Tumber, A., Salah, E., Jabbary, M., Nakashima, Y., Schnaubelt, L. I., Basak, S., Alshref, F. M., Brewitz, L., & Schofield, C. J. (2025). Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00586
Vancouver
Corner TP, Tumber A, Salah E, Jabbary M, Nakashima Y, Schnaubelt LI, et al. Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00586
BibTeX
@article{Corner2025,
author = {Corner, Thomas P and Tumber, Anthony and Salah, Eidarus and Jabbary, Mohammadparsa and Nakashima, Yu and Schnaubelt, Lara I and Basak, Shyam and Alshref, Faisal M and Brewitz, Lennart and Schofield, Christopher J},
title = {Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00586}
}
EUVIMED